Photobiomodulation therapy inhibits oral submucous fibrosis in mice.
Oral Dis
; 26(7): 1474-1482, 2020 Oct.
Article
en En
| MEDLINE
| ID: mdl-32391600
ABSTRACT
OBJECTIVES:
Oral submucous fibrosis (OSMF) is a chronic inflammatory disease and a potentially malignant oral disorder. However, the best therapeutic treatment for OSMF remains uncertain. Our previous study showed that photobiomodulation (PBM) therapy and forskolin could reduce arecoline-induced fibrosis reactions via the cAMP pathway. The present study aimed to establish an animal model of areca nut extract (ANE)-induced OSMF and to evaluate the therapeutic potential of PBM and forskolin for ANE-induced OSMF. SUBJECTS ANDMETHODS:
The mice were divided into five groups. The buccal tissues were harvested for histomorphological analysis and immunoblotting.RESULTS:
Our results showed that PBM significantly reduced the development of ANE-induced OSMF, quantified by changes in submucosal layer thickness and collagen deposition. Additionally, PBM could extensively reduce the protein expression of the fibrotic marker genes alpha-smooth muscle actin (α-SMA) and connective tissue growth factor (CTGF) in buccal submucous lesions. However, forskolin treatment significantly decreased the protein expression of fibrotic marker genes but slightly decreased the observed histomorphological changes.CONCLUSIONS:
We established an ANE-induced OSMF mouse model, which also provided a model for the development of a therapeutic treatment for OSMF. The anti-fibrotic effects of PBM and forskolin may be useful for clinical interventions.Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Fibrosis de la Submucosa Bucal
/
Terapia por Luz de Baja Intensidad
Tipo de estudio:
Prognostic_studies
Límite:
Animals
Idioma:
En
Revista:
Oral Dis
Asunto de la revista:
ODONTOLOGIA
Año:
2020
Tipo del documento:
Article
País de afiliación:
Taiwán